COPENHAGEN/LONDON (Reuters) - Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its ...

Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on ...

COPENHAGEN/LONDON June 24 - Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Novo said on Friday its current CEO will step down The obesity drug maker has struggled to compete against U.S. rival Eli Lilly American CEO may be better to deal with a Trump admin, analysts said ...